Arrow
Arrow
Slider

Please find below the latest news from Premaitha Health. We also share this news across social media networks.

  • 12 July 2017 - Investment Agreement Extension with Thermo Fisher Scientific +

    Premaitha Health Plc
    (“Premaitha”, the “Company” or the “Group”)

    Investment Agreement Extension with Thermo Fisher Scientific

    Manchester, UK – 12 July 2017 - Premaitha Health Plc (AIM: NIPT), a leading international molecular diagnostics group focused on non-invasive prenatal testing, is pleased to announce that it has entered into a further extension of the investment agreement with Thermo Fisher Scientific (“Thermo Fisher”) announced on 14 December 2015 and extended as announced on 23 September 2016, further developing

    Read More
  • 10 July 2017 - Premaitha announces two laboratory hub contracts in South East Asia +

    Premaitha Health plc
    (“Premaitha” or the “Company” or the “Group”)

    Premaitha announces two laboratory hub contracts in South East Asia

    Manchester, UK – 10 July 2017: Premaitha Health plc (AIM: NIPT), a leading international molecular diagnostics group focused on non-invasive prenatal testing (“NIPT”), announces that it has signed contracts with two significant laboratories in South East Asia through its Taiwanese subsidiary, Yourgene Bioscience (“Yourgene”).

    The agreements have been signed with two partners for laboratories which

    Read More
  • 3 July 2017 - Litigation Update +

    Premaitha Health PLC
    (“Premaitha” or the “Company”)

    Litigation Update

    Manchester, UK – 3 July 2017: Premaitha Health PLC (AIM: NIPT), a leading international molecular diagnostics group focused on non-invasive prenatal testing (“NIPT”), provides the following update on the legal proceedings in connection with patent infringement suits filed by Illumina, Inc. and others (together the “Claimants”). The patents in issue in these proceedings fall into three families: European Patent (UK) 0 994 963; European Patent (UK)

    Read More
  • 26 June 2017 - The IONA® test updated to include the first trimester combined test result +

    Premaitha Health PLC
    (“Premaitha” or the “Company”)

    The IONA ® test updated to include the first trimester combined test result

    Manchester, UK – 26 June 2017: Premaitha Health, a leading international molecular diagnostics group focused on non-invasive prenatal testing (“NIPT”), is pleased to announce enhancements to the IONA ® test, which now incorporates the first trimester combined test risk score into its software.

    The IONA ® test is Premaitha’s leading CE-marked non-invasive prenatal test which

    Read More
  • 16 June 2017 - Premaitha launches Sage™ prenatal screening solution in Hong Kong +

    Premaitha Health PLC
    (“Premaitha” or the “Company”)

    Premaitha launches Sage™ prenatal screening solution in Hong Kong

    Manchester, UK – 16 June 2017: Premaitha Health PLC (AIM: NIPT), a leading international molecular diagnostics group focused on non-invasive prenatal testing (“NIPT”), announces the launch of Sage™, an NIPT solution incorporating additional prenatal screening analysis tools.

    Sage™ is an advanced NIPT analysis solution, available through Yourgene Bioscience Singapore (“Yourgene”), which was acquired by Premaitha in March 2017. It

    Read More
  • 5 June 2017 - India Business Update +

    Premaitha Health plc
    (“Premaitha” or the “Company” or the “Group”)

    India Business Update

    Manchester, UK – 5 June 2017: Premaitha Health plc (AIM: NIPT), a leading international molecular diagnostics group focused on non-invasive prenatal testing, is pleased to provide an update on commercial progress in India.

    Yourgene Bioscience (“Yourgene”), acquired by Premaitha in March 2017, is now firmly established as one of India’s leading providers in the emerging non-invasive prenatal testing (“NIPT”) market,  with representation

    Read More
  • 26 May 2017 - Premaitha completes IONA test validation on Thermo Fisher’s Ion S5 instrument +

    Premaitha Health PLC
    (“Premaitha” or the “Company”)
     
    Premaitha completes IONA test validation on Thermo Fisher’s Ion S5 instrument
     
    Manchester, UK – 26 May 2017: Premaitha Health plc (AIM: NIPT, “Premaitha” or the “Company”), a leading international molecular diagnostics group focused on prenatal testing, announces that the IONA ® test, the Company’s CE-IVD non-invasive prenatal test (“NIPT”), has been validated for use on Thermo Fisher Scientific’s Ion S5 range of instruments.
     
    The validation
    Read More
  • 19 May 2017 - Premaitha welcomes NIPT recommendation in France +

    Premaitha Health PLC
    (“Premaitha” or the “Company”)
     
    Premaitha welcomes NIPT recommendation in France
     
    Haute Authorité de Santé recommends introduction of NIPT for high and intermediate risk women
     
    Manchester, UK – 19 May 2017: Premaitha Health plc (AIM: NIPT, “Premaitha” or the “Company”), a leading international molecular diagnostics group focused on prenatal testing, welcomes the recommendation by the Haute Authorité de Santé (“HAS”), the French National Authority for Health, to make non-invasive prenatal
    Read More
  • 12 May 2017 - Update Re. Swiss Customer +

    Premaitha Health PLC
    (“Premaitha” or the “Company”)

    Update Re. Swiss Customer

    Manchester, UK – 12 May 2017: Premaitha Health plc (AIM: NIPT, “Premaitha” or the “Company”), a leading international molecular diagnostics group focused on prenatal testing, announces that the Company’s application for its Swiss customer, Genoma SA (“Genoma”), to be placed into bankruptcy for non-payment of debts has been successful (the “Ruling”).

    As previously announced in the Company’s interim results (see RNS announcement on 21

    Read More
  • 13 March 2017 - Premaitha Raises Awareness of the IONA® Test at Key International Medical Events +

    Premaitha Health PLC
    (“Premaitha” or the “Company”)

    Premaitha Raises Awareness of the IONA ® Test at Key International Medical Events

    Manchester, UK – 13 March 2017: Premaitha Health PLC (AIM: NIPT), a leading international molecular diagnostics group focused on prenatal testing, will be attending a series of key international fetal medicine and OB/GYN events during March to broaden awareness of the IONA ® test. The events will include:

    The Royal College of Obstetricians and Gynaecologists

    Read More
  • 1
  • 2
  • 3
  • 4
  • 5
  • 6
  • 7
Pregnant lady sitting at table with Laptop

Investor Relations
Ben Simons / Fiona Henson
Vigo Communications
180 Piccadilly
London W1J 9HF
premaitha@vigocomms.com
T : +44 (0) 20 7830 9700

Two business people looking at computer screen